50% Hemolysis Rate (CH50) Assay: Operating Procedure and Technical Guidelines

The 50% hemolysis rate experiment, widely known as the CH50 assay, is a quantitative laboratory technique used to determine the dilution or activity level at which complement-containing serum lyses half of a standardized suspension of antibody-sensitized erythrocytes. This article provides a comprehensive technical overview of the operating procedure, sample requirements, calculation methodology, and quality control considerations in accordance with recognized standards such as ISO 10993-4 and GB/T 16886.4. It serves as a practical reference for clinical immunology laboratories, biocompatibility testing facilities, and research institutions evaluating hemolytic activity.

Technical Overview

The 50% hemolysis rate experiment (CH50 assay) is a classical quantitative method in immunology and biocompatibility evaluation. It measures the total hemolytic activity of complement by determining the exact amount or dilution of a serum sample required to lyse 50% of a standardized population of antibody-sensitized sheep red blood cells (SRBCs). When complement proteins are activated through the classical pathway, they assemble the membrane attack complex on the erythrocyte surface, causing cell membrane perforation and the release of hemoglobin into the surrounding medium.

The relationship between complement quantity and the percentage of lysed cells follows a sigmoidal dose-response curve rather than a linear one. To linearize this relationship, laboratories apply the von Krogh transformation, in which the logarithm of Y/(1-Y), where Y is the fractional hemolysis, is plotted against the logarithm of the serum volume or dilution. The point at which the resulting straight line intersects the value corresponding to 50% hemolysis defines the CH50 endpoint. This approach offers significantly higher precision than visual endpoint titration, because the steepest portion of the hemolysis curve occurs near the 50% point, making the measurement maximally sensitive to small changes in complement activity.

Today, the assay is performed in clinical immunology laboratories for the functional assessment of the classical complement pathway, in accredited third-party laboratories for the hemocompatibility evaluation of blood-contacting medical devices under ISO 10993-4 and GB/T 16886.4, and in pharmaceutical development for the hemolytic safety screening of injectable products and biological preparations.

Testing Samples

Clinical Serum Samples

Human venous blood is collected using plain tubes without anticoagulant and allowed to clot at room temperature for 30 to 60 minutes before centrifugation. Serum is preferred because common anticoagulants such as EDTA chelate calcium and magnesium ions, which are essential cofactors for complement activation and would invalidate the assay. Samples should be separated promptly, stored at 2 to 8 degrees Celsius if tested within 24 hours, or frozen at minus 70 degrees Celsius for longer storage, and repeated freeze-thaw cycles must be avoided because they degrade complement activity.

Medical Device Extracts

For blood-contacting devices and biomaterials, extraction is performed according to the conditions specified in ISO 10993-4 and GB/T 16886.4, typically using compatible extraction vehicles and standardized surface-area-to-volume ratios. The resulting extract is incubated with erythrocytes, and the degree of hemoglobin release is used to characterize the hemolytic potential of the material. ASTM F756 provides complementary guidance on the evaluation of material hemolytic properties.

Biological Products and Pharmaceuticals

Injectable formulations, antibody-based therapeutics, vaccines, and adjuvant candidates may be screened for hemolytic activity. Serial dilutions of the test article are incubated with a standardized erythrocyte suspension to determine the concentration that produces 50% hemolysis, defined as the HC50 value.

Animal Serum Samples

Serum from species such as guinea pig, rabbit, rat, or mouse is frequently analyzed in preclinical studies and immunotoxicology investigations to assess complement activation status and species-specific complement activity.

Testing Items

The 50% hemolysis rate experiment encompasses several related testing endpoints depending on the study objective:

• CH50 determination: functional quantification of total classical pathway complement activity, expressed as units per milliliter of serum.
• AH50 determination: assessment of alternative pathway activity using rabbit erythrocytes and magnesium-only buffer conditions.
• HC50 determination: identification of the test article concentration or extract dilution that produces 50% hemolysis of the erythrocyte suspension.
• Hemolysis ratio calculation: percentage of hemolysis induced by a material or substance relative to complete hemolysis controls.
• Complement activation markers: supplementary measurements such as C3a, C5a, SC5b-9, Bb, and C4d fragments for pathway-specific evaluation under ISO 10993-4.

Testing Methods

Reagents and Equipment

• Sheep red blood cell suspension, typically prepared at 2% to 5% concentration in buffered diluent.
• Rabbit anti-sheep erythrocyte antiserum (hemolysin or amboceptor), titrated to determine the optimal sensitizing dilution.
• Veronal-buffered saline containing calcium and magnesium ions, serving as the assay diluent.
• Spectrophotometer or microplate reader capable of measurement at 541 nanometers, the absorption maximum of oxyhemoglobin.
• Constant-temperature water bath or incubator set at 37 degrees Celsius.
• Refrigerated centrifuge for separating intact cells from hemoglobin-containing supernatant.
• Calibrated pipettes, dilution tubes or 96-well microplates, and volume verification aids such as a hemocytometer for cell counting.

Preparation of Sensitized Erythrocytes

Sheep blood obtained in anticoagulant is washed three to five times in buffered saline by centrifugation until the supernatant is clear. A defined cell suspension is prepared, and the packed cells are incubated with the optimal dilution of hemolysin at 37 degrees Celsius for approximately 30 minutes with gentle mixing. This coating step ensures that complement fixation occurs through the classical pathway when the sensitized cells are exposed to the serum sample.

Serial Dilution and Incubation

The test serum is diluted in a geometric series across a series of tubes or wells, and a fixed volume of the standardized sensitized erythrocyte suspension is added to each dilution. The reaction mixtures are incubated at 37 degrees Celsius for 30 to 60 minutes with periodic gentle agitation. After incubation, the tubes are centrifuged to pellet the intact erythrocytes, and the optical density of each supernatant is measured at 541 nanometers.

Controls

Each assay run must include the following controls to validate the results:

• Complete hemolysis control: erythrocytes lysed with distilled water or saponin, defining the 100% hemolysis reference.
• Blank control: erythrocytes incubated with buffer only, defining the zero-hemolysis baseline.
• Spontaneous hemolysis control: cells incubated without serum to monitor intrinsic cell stability.
• Reference serum control: a pooled serum of known CH50 activity to verify inter-assay consistency.
• Reagent control: sensitized cells exposed to diluent to confirm the absence of nonspecific lysis.

Calculation and Data Interpretation

The fractional hemolysis Y for each dilution is calculated as the absorbance of the test sample minus the absorbance of the blank, divided by the absorbance of the complete hemolysis control minus the absorbance of the blank. The value of Y/(1-Y) is then computed for each tube, and the logarithm of this ratio is plotted against the logarithm of the corresponding serum volume. Because Y equals 0.5 when Y/(1-Y) equals 1, the CH50 corresponds to the serum volume read at the zero intercept of the log-transformed regression line. The reciprocal of this volume, adjusted for the dilution factor and reaction volume, yields the complement activity in units per milliliter. Dilutions yielding hemolysis between 20% and 80% contribute the most reliable data points and should anchor the regression analysis.

Quality Assurance

Accuracy depends on rigorous standardization of cell concentration, incubation time, temperature, buffer ionic strength, and sensitization conditions. Laboratories should verify pipette calibration, use freshly prepared or properly stored reagents, establish acceptable hemolysin titers before each batch, and apply acceptance criteria for control performance. Participation in inter-laboratory comparison programs and adherence to documented standard operating procedures aligned with ISO 10993-4, GB/T 16886.4, and ASTM F756 ensures reproducible, defensible results.

Applications

The 50% hemolysis rate experiment supports a wide spectrum of clinical, regulatory, and research applications:

• Clinical diagnosis of classical pathway complement deficiencies and monitoring of diseases involving complement consumption, such as systemic lupus erythematosus, glomerulonephritis, and immune complex disorders.
• Hemocompatibility evaluation of blood-contacting medical devices, catheters, stents, dialysis membranes, and blood bags in compliance with ISO 10993-4 and GB/T 16886.4.
• Safety assessment of intravenous pharmaceuticals, biological products, nanoparticles, and contrast agents to screen for dose-dependent hemolytic effects.
• Functional verification of complement activity in serum lots intended for use in complement-dependent cytotoxicity assays and serological testing.
• Immunotoxicology research investigating complement activation induced by drugs, excipients, or biomaterial surfaces.
• Educational training in clinical immunology laboratory courses, where the assay illustrates antibody-complement cooperation and quantitative endpoint analysis.

FAQ

Why is the 50% hemolysis point used instead of 100% hemolysis?

The complement titration curve is sigmoidal and steepest near the midpoint. Small changes in complement activity produce the largest measurable change in hemolysis percentage around the 50% point, whereas the curve flattens near complete hemolysis. Selecting the 50% endpoint therefore maximizes analytical sensitivity and precision.

Can plasma be used instead of serum?

Plasma anticoagulated with EDTA is unsuitable because it chelates the divalent ions required for complement activation. Heparinized plasma may be acceptable in some protocols, but serum collected from clotted blood remains the recommended sample type for CH50 determination.

What are typical reference values?

Reference intervals vary with the erythrocyte preparation, incubation conditions, and calculation method established by each laboratory. Human serum generally falls within an approximate range of 60 to 150 units per milliliter, and each facility must validate its own interval using locally established methods and control sera.

What is the difference between CH50 and AH50?

CH50 measures classical pathway activity using antibody-sensitized sheep erythrocytes in buffer containing both calcium and magnesium. AH50 measures alternative pathway activity using unsensitized rabbit erythrocytes in buffer containing magnesium only. Comparing both values helps localize a complement deficiency to a specific pathway or shared terminal component.

What interferences should be considered?

Grossly hemolyzed or lipemic samples, bacterial contamination, repeated freeze-thaw cycles, prolonged room-temperature storage, and residual anticoagulants can all distort results. Test articles that are strongly colored or absorb near 541 nanometers require blank correction, complementary analytical methods, or spectrophotometric adaptation to avoid falsely elevated hemolysis readings.

How should samples be shipped to the laboratory?

Serum should be separated from the clot, frozen on dry ice, and shipped with temperature monitoring to prevent complement degradation. Medical device samples should be extracted under conditions documented in the test plan, and extracts should be tested promptly according to the stability window established during method validation.

How long does the assay take to complete?

A standard CH50 determination, including reagent preparation, sensitization, dilution, incubation, absorbance reading, and calculation, can typically be completed within one working day. Studies involving medical device extraction or method validation require additional time for preconditioning and control runs.